Visitors Now:
Total Visits:
Total Stories:
Profile image
By Global Market Insights Inc.
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Japan Dyslipidemia Treatment Drugs Industry Forecast to 2023

Sunday, October 2, 2016 22:51
% of readers think this story is Fact. Add your two cents.

(Before It's News) adds “Dyslipidemia -Japan Drug Forecast and Market Analysis to 2023” new report to its research database. The report spread across 252 pages with table and figures in it.

The report expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn).

The report estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.

Browse full table of contents and data tables at

In the 2013 base year, the only dyslipidemia drugs included in this forecast that were available in Japan were the statins, ezetimibe, and the omega-3 fish oil agents. Of these, the statins contributed to the vast majority of sales, with the drug class contributing $793m, or 76% of the total Japanese market share.


-Overview of Dyslipidemia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in Japan from 2013-2023.
-Analysis of the impact of key events as well the drivers and restraints affecting Japan Dyslipidemia market.
Request a sample copy at  

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Dyslipidemia.
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2013-2023 in Japan.

Enquiry before Buying at   

To receive personalized assistance write to us @ with the report title in the subject line along with your questions or call us at +1 866-764-2150

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.